Clinical Trial: Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients With B-Cell Acute Lymphoblastic Leukemia With an Option of Exten

Brief Summary: A Phase I/II, Multi-Center, Open-Label, Repeat-Dose Study of Forodesine Hydrochloride Infusion in Patients with B-cell Acute Lymphoblastic Leukemia with an Option of Extended Use of Forodesine Hydrochloride

Detailed Summary:
Sponsor: BioCryst Pharmaceuticals

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: BioCryst Pharmaceuticals

Dates:
Date Received: February 8, 2006
Date Started: September 2004
Date Completion:
Last Updated: January 19, 2012
Last Verified: January 2012